AbbVie (ABBV) said Tuesday that the European Commission granted marketing authorization to giant cell arteritis treatment Rinvoq for adult patients.

The approval was based on results from a phase 3 trial, which met its primary and key secondary endpoints, the company said.

The drug has been previously approved in seven other indications, including rheumatoid arthritis.

Giant cell arteritis is an inflammatory autoimmune disease of large blood vessels.